The use of short-acting-beta-2-agonists (SABA) has been associated with prediction of increased risks of chronic obstructive pulmonary disease (COPD) exacerbations in patients, according to a recent study entitled “Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease” published in…
News
ieCrowd™ recently announced the achievement of a crucial milestone in the commercial advancement of Smart Oxygen, the firm’s supplemental oxygen delivery device. The Smart Oxygen device is being advanced by ieCrowd’s subsidiary Smart Oxygen Solutions and has the ability to automatically adjust to the patient’s need for oxygen, even if those demands are constantly changing, through analyzing the level of…
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by progressive breathlessness, acute exacerbations, increased coughing, mucus, and a feeling of tightness in patients’ chest. Usually if the exacerbation symptoms are not detected and treated on time, they can escalate, leading to a more acute scenario, which can diminish…
News
Review of Recent European Respiratory Society Statement Explores Role of Physical Activity in COPD
In a recent article published in the Polish Archives of Internal Medicine, Richard ZuWallack from the Department of Pulmonary and Critical Care, St. Francis Hospital and Medical Center in Hartford, Connecticut conducted a review exploring the concept of physical activity in patients with Chronic Obstructive Pulmonary Disease.
In a new study entitled “Defining the Asthma-COPD overlap syndrome in a COPD cohort,” authors show that using clinical asthma features is an effective diagnosis strategy to identify patients with asthma–chronic obstructive pulmonary disease (COPD) overlapping syndrome (ACOS). The study was published in the journal…
CSL Behring, a global leader in the plasma protein therapeutics industry, has just announced its breakthrough maintenance treatment for patients with emphysema with documented severe A1-PI deficiency (AATD). Respreeza® has received marketing authorization in all states in the European Union (EU). Respreeza is a highly purified Alpha-1 protein derived from human plasma…
Chronic Obstructive Pulmonary Disease (COPD) includes a group of progressive lung diseases such as emphysema, chronic bronchitis, non-reversible asthma, and some forms of bronchiectasis. COPD typically manifests itself in individuals who have had a long-term contact with harmful pollutants,a history of smoking, or who have a genetic predisposition to the disease. According to the…
Boehringer Ingelheim recently released a report on the company’s findings from the Phase IIIb OTEMTO 1 (NCT01964352) & 2 (NCT02006732) clinical trials, which are testing combination treatment Spiolto® Respimat® (tiotropium/olodaterol) for patients with chronic obstructive pulmonary disease (COPD). The update is published in the…
A study recently published in the journal Oxidative Medicine and Cellular Longevity reviewed the link between reactive oxygen species (ROS), stem cell aging and lung disorders like chronic obstructive pulmonary disease (COPD). The study is titled “Reactive Oxygen Species in Mesenchymal Stem Cell Aging:…
Boehringer Ingelheim recently announced the completion of the phase IIIb OTEMTO® 1 & 2 trials for their pipeline drug STIOLTO RESPIMAT, and have published the study data online in the Respiratory Medicine journal. The new data reveals that the drug has the potential to improve clinical outcomes in patients with…
Recent Posts
- How a cornfield taught me to claim space while living with COPD
- Tozorakimab reduced COPD flare-ups in top-line Phase 3 trial data
- Navigating the blind curves of COPD so you can still get where you are going
- From bird lice to COPD sensations, the body always tells the truth
- We should practice being calm for the moments when we are not